Herbert Irving Comprehensive Cancer Center
Investigator
Brian Henick, MD
Phone
212-305-5098
Email
bh2682@cumc.columbia.edu
Dr. Henick is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract. As the Associate Director of Experimental Therapeutics and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Dr. Henick’s clinical care and research are aligned to improve the effectiveness of, and limit toxicity from, emerging cancer treatments. These efforts entail clinical trials that Dr. Henick has written and leads to study novel therapeutic approaches and to reduce steroid dependence among patients experiencing adverse events from immunotherapy.

Clinical Studies Managed By This Investigator:
Condition Study Title
Lung Cancer [ CLOSED ] Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer [ CLOSED ] Study of RO7198457 in locally advanced or metastatic tumors
Cancer [ CLOSED ] Molecular Analysis for Therapy Choice (MATCH)
Cancer [ CLOSED ] Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
Lung Cancer [ CLOSED ] Study of Drug in Patients with Early Stage Non-Small Cell Lung Cancer
Solid Tumors [ CLOSED ] Study of Drug Alone and In Combination with Nivolumab in Advanced Solid Tumors
Solid Tumors [ CLOSED ] Study of Experimental Drug GSK3359609 in Patients with Advanced Solid Tumors
Sarcoma [ CLOSED ] Study of HuMax-AXL-ADC in Patients with Sarcoma
Cancer [ CLOSED ] Study of a Neoantigen Cancer Vaccine in Patients with Advanced Solid Tumors (Bladder, Colon, Stomach, Lung, Esophageal, or Rectal Cancer)
Solid Tumors [ CLOSED ] A Study of BA3021 in Patients with Advanced Solid Tumors (Lung Cancer, Triple Negative Breast Cancer, or Soft Tissue Sarcoma)
Lung Cancer [ CLOSED ] GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (Non-small Cell Lung Cancer)
Solid Tumors [ CLOSED ] A Study of ASP1951 in Subjects with Advanced Solid Tumors
Lung Cancer [ CLOSED ] Radiation and Immune Checkpoints Blockade in Metastatic Non-Small Cell Lung Cancer (NSCLC)
Cancer [ CLOSED ] Study of Glutaminase Inhibitor CB-839 HCl in Subjects with Advanced Solid Tumors
Cancer [ CLOSED ] Study of A Vaccine Targeting Shared Neoantigens in Subjects with Advanced Solid Tumors
Cancer [ CLOSED ] Study of ApricityOncology Smartphone Application Monitoring and Reporting Side Effects to their Nurses and Doctors
Cancer [ CLOSED ] Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Lung Cancer [ CLOSED ] Study of M7824 and cCRT in Patients with Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Lung Cancer [ CLOSED ] Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Lung Cancer [ CLOSED ] Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)
Lung Cancer [ CLOSED ] Study of Telaglenastat in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer [ CLOSED ] Tomivosertib With Anti-PD-(L)1 in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Cancer [ CLOSED ] Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Autoimmune Disorders [ CLOSED ] Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Head and Neck Cancer [ CLOSED ] Study of NBTRX3 in Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)
Cancer [ CLOSED ] Study of T Plex in Patients with Advanced or Metastatic Solid Tumors